KRAS FFPE Controls from AcroMetrix® by Life Technologies™
by Suzanne Clancy - 07/19/11
CARLSBAD, Calif., July 19, 2011 – Life Technologies Corporation today announced that the company has introduced its Applied Biosystems™ AcroMetrix® KRAS FFPE Process Controls, the only currently on the market that enable laboratories to assess and monitor an entire workflow from FFPE sample to result without using archived tumor material.
The AcroMetrix® KRAS FFPE Process Controls are designed to emulate FFPE laboratory samples through all steps of the workflow process including deparaffinization and extraction. The kit comprises controls for seven of the most commonly assayed KRAS gene mutations: G12A, G12C, G12D, G12R, G12S, G12V, and G13D, as well as a wild type (WT) control.
Approximately 30-40% of colorectal cancers harbor a KRAS mutation. The American Society for Clinical Oncology recommends that all patients diagnosed with metastatic colorectal cancer who are candidates for anti-EGFR therapy be tested for KRAS mutations in a CLIA laboratory in order to predict drug efficacy.
AcroMetrix® KRAS FFPE Process Controls are manufactured by mixing KRAS mutation-positive cells with a co-polymer, creating a synthetic tissue, which is then formalin-fixed and paraffin-embedded. The kit consists of eight vials, each containing a 10 µm FFPE tissue section created from cells harboring a single mutation; each 10 µm section contains >200 ng of DNA. All AcroMetrix® products are manufactured in accordance with ISO 17511 for consistent performance across lots. The above referenced KRAS FFPE Process Controls products are for Research Use Only. Not intended for diagnostic use.
About Life Technologies
Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com/. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.